Adlyxin (lixisenatide) / Zealand Pharma, Sanofi, Royalty - LARVOL DELTA

GLP-1 Receptor Agonists Versus SGLT-2 Inhibitors in Fibrotic MASLD With Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Analysis of Hepatic and Mortality Outcomes (ACG 2026) - "Cohort 1 received GLP-1RAs (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide); Cohort 2 received SGLT-2is (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin)... Post-matching cohorts were balanced (47.4% female, ~69% White). New cirrhosis did not differ significantly (0.11% vs. 0.15%; RR 0.74, 95% CI 0.48â1.13; p=0.16)."

Clinical • Real-world • Real-world evidence • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Pancreatitis • Type 2 Diabetes Mellitus

GLP-1 Receptor Agonists and Anorectal Outcomes in Type 2 Diabetes: A Propensity-Matched Cohort Study (ACG 2026) - "GLP-1 RA users received semaglutide, tirzepatide, liraglutide, dulaglutide, or lixisenatide... After matching, 256,212 patients were included in each cohort. Mean age was 65.0±11.5 years in GLP-1 RA users and 64.7±12.1 years in comparators; 51.3% and 49.7% were female. Baseline variables were balanced, although BMI remained higher in GLP-1 RA users (35.7±7.6 vs 32.3±7.4; standardized difference 0.457)."

Colorectal Cancer • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Metabolic Disorders • Type 2 Diabetes Mellitus

Post-ERCP Pancreatitis Risk With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes: A Multicenter Propensity-Matched Analysis (ACG 2026) - "GLP-1RA exposure was defined using RxNorm codes for semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, tirzepatide, or GLP-1RA class codes... Before matching, 488 GLP-1RA users and 1,805 non-GLP-1 users underwent ERCP. After PSM, 407 patients remained in each cohort. GLP-1RA use was not associated with increased PEP (6.39% vs 7.13%; aOR 0.89, 95% CI 0.51â1.54; p=0.68)."

Clinical • Diabetes • Metabolic Disorders • Pancreatitis • Type 2 Diabetes Mellitus

Cohort Study: Post-ERCP Pancreatitis Risk With GLP-1 Receptor Agonists in 51,392 Patients With Obesity (ACG 2026) - "GLP-1RA exposure was defined using RxNorm codes for semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, tirzepatide, or GLP-1RA class codes... Before matching, 709 GLP-1RA users and 50,683 non-users underwent ERCP. After PSM, 706 patients remained in each cohort. PEP did not differ significantly between GLP-1RA users and non-users (7.08% vs 8.50%; aOR 0.82, 95% CI 0.56â1.21; p=0.32)."

Clinical • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Pancreatitis • Type 2 Diabetes Mellitus

Peri-ERCP Gastrointestinal Safety of Chronic GLP-1 vs SGLT2 Inhibitor Therapy: A US Propensity-Matched Cohort (ACG 2026) - "GLP-1 RAs included semaglutide, liraglutide, dulaglutide, exenatide, and lixisenatide; tirzepatide was excluded (dual GIP/GLP-1 agonist)...1:1 matching balanced demographics, T2D, obesity, hyperlipidemia, gallstones, cholangitis, alcohol use, CKD, cirrhosis, smoking, opioids, NSAIDs, steroids, and anticoagulants (post-match SMDs < 0.05)... 1,947 GLP-1 RA and 1,432 SGLT2i patients met criteria; 1,432 matched pairs retained. The composite outcome occurred in 144/1,432 (10.1%) GLP-1 RA vs 162/1,432 (11.3%) SGLT2i (RR 0.89, 95% CI 0.72â1.10). Nausea/vomiting (8.4% vs 9.8%; RR 0.86, 0.68â1.08) and ileus (17/1,432 [1.2%] vs 18/1,432 [1.3%]; RR 0.94, 0.49â1.83) did not differ."

Clinical • Chronic Kidney Disease • Dyslipidemia • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Immunology • Inflammation • Obesity • Pancreatitis • Pneumonia • Rheumatoid Arthritis

Post-Colonoscopy GLP-1 Receptor Agonist Use and Subsequent Bowel Preparation Outcomes: A Propensity-Matched Real-World Cohort Study (ACG 2026) - "Cohort 1 initiated a GLP-1RA (semaglutide, tirzepatide, liraglutide, dulaglutide, or lixisenatide) following index colonoscopy... After matching, cohorts were well balanced (66.7% female, 56.7% White). GLP-1RA use was associated with significantly lower rates of inadequate bowel preparation (3.8% vs 8.4%; RR 0.44, 95% CI 0.41â0.48; p< 0.001), need for additional bowel regimen (9.3% vs 13.2%; RR 0.71; p< 0.001), and repeat colonoscopy (7.6% vs 13.0%; RR 0.58, 95% CI 0.55â0.61; p< 0.001). Colonoscopy-related complications were also less frequent (0.21% vs 0.58%; RR 0.36; p< 0.001)."

Clinical • Real-world • Real-world evidence • Colorectal Cancer • Gastrointestinal Disorder • Inflammatory Bowel Disease

Clinical Outcomes of GLP-1 Receptor Agonist Use in Patients With Pre-Existing Gastroparesis With Type 2 Diabetes and/or Obesity (ACG 2026) - "Adults (â¥18 years) with confirmed gastroparesis (ICD-10 K31.84) and type 2 diabetes and/or obesity prior to GLP-1 initiation were stratified into GLP-1 users (semaglutide, tirzepatide, liraglutide, dulaglutide, lixisenatide, exenatide) vs. non-users... Of 138,793 eligible gastroparesis patients, 1,800 received GLP-1 agonists. After 1:1 PSM (n=1,792/cohort), GLP-1 use was associated with lower 1-year mortality (3% vs. 5.7%, RR 0.53, 95% CI 0.38-0.73, p< 0.001), SBO/ileus (1.3% vs."

Clinical • Clinical data • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Infectious Disease • Metabolic Disorders • Obesity • Pneumonia • Respiratory Diseases • Type 2 Diabetes Mellitus

Glucagon-Like Peptide-1 Receptor Agonists Affect the Progression of Barrett's Esophagus (ACG 2026) - "Short acting GLP-1RA are exenatide, lixisenatide and liraglutide, whereas long acting GLP-1RA are semaglutide and dulaglutide. After PSM, 2,473 patients were identified in each of the groups in the short-acting GLP-1RA analysis, and 21,406 patients were identified in the each of the groups in the long-acting GLP-1RA analysis. In the short-acting analysis, the incidence of progression to dysplasia over the 10-year follow-up was 8.1% (187/2,316) in users compared with 5.9% (135/2,302) in controls (RR, 1.37; 95% CI, 1.11â1.70; P = 0.003). The incidence of EAC in this analysis was too low to be reported."

Barrett Esophagus • Esophageal Adenocarcinoma • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Obesity • Solid Tumor

GLP-1 Receptor Agonists and Respiratory Outcomes in Achalasia: A Real-World Propensity-Matched Cohort Study (ACG 2026) - "Adults with achalasia (ICD-10 K22.0) who received GLP-1RAs (liraglutide, semaglutide, dulaglutide, exenatide, or lixisenatide) were compared with achalasia patients without GLP-1RA exposure. Among 68,630 patients with achalasia, 1,700 received GLP-1RAs. After propensity score matching, 1,695 patients remained in each cohort. GLP-1RA use was associated with a significantly lower risk of aspiration pneumonia compared with non-use (1.0% vs 4.8%; RR 0.21, 95% CI 0.12â0.35; HR 0.22, 95% CI 0.13â0.37; p< 0.001)."

Clinical • Real-world • Real-world evidence • Amyotrophic Lateral Sclerosis • Cardiovascular • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • CNS Disorders • Diabetes • Dyslipidemia • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Movement Disorders • Nephrology • Obesity • Obstructive Sleep Apnea • Parkinson's Disease • Pneumonia • Pulmonary Disease • Rare Diseases • Renal Disease • Respiratory Diseases • Sleep Disorder

GLP-1 Agonist Use and Outcomes in Connective Tissue Disease-Associated Interstitial Lung Disease (ACR Convergence 2026) - "Patients were categorized as GLP-1 RA users (including semaglutide, dulaglutide, liraglutide, albiglutide, exenatide, lixisenatide) or non-users, and outcomes were evaluated over a 5-year follow-up. In this large propensity score-matched cohort of patients with CTD-ILD, GLP-1 RA use was associated with a significantly reduced risk of mortality. These findings suggest a potential protective role of GLP-1-based therapies and support prospective studies to further define their role in risk modification and disease outcomes in CTD-ILD."

Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Genetic Disorders • Heart Failure • Inflammatory Arthritis • Interstitial Lung Disease • Metabolic Disorders • Myocardial Infarction • Myositis • Obesity • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Scleroderma • Sjogren's Syndrome • Systemic Sclerosis • Type 2 Diabetes Mellitus

The GLP-1 Agonist Paradox in Parkinson’s Disease: A Comparative Analysis of Lixisenatide and Exenatide Phase III Trial Outcomes and Neuroprotective Mechanisms (MDS Congress 2026) - No abstract available

P3 data • CNS Disorders • Movement Disorders • Parkinson's Disease

The Impact of GLP-1 Medications and the Development of Patulous Eustachian Tube Dysfunction (AAO-HNSF 2026) - "392,953 patients aged ≥18 with an overweight or obese diagnosis (ICD-10-CM: E66) prescribed GLP-1 medication (exenatide, tirzepatide, lixisenatide, semaglutide, liraglutide, or dulaglutide) we identified between 1/1/2022 and 1/1/2025. GLP-1-based treatments were significantly associated with the development of PETD and any ETD. General providers and hearing specialists should be aware of this potential risk when managing patients who take GLP-1-related medications."

Allergic Rhinitis • Asthma • Genetic Disorders • Immunology • Inflammation • Obesity • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Do GLP-1 Receptor Agonists Increase Thyroid Cancer Risk? Reassuring Evidence from over Two Million Patients (AAO-HNSF 2026) - "Introduction: Use of glucagon-like peptide-1 receptor agonists (GLP1RA) has rapidly expanded due to benefits in glycemic control, weight loss, and cardiovascular risk reduction...GLP1RA medications included dulaglutide, exenatide, lixisenatide, liraglutide, semaglutide, and tirzepatide... This is the largest study in the US evaluating thyroid cancer risk in the GLP1RA user population. There were few incident thyroid cancer cases and no overall increased risk of incident thyroid cancer compared with non-users."

Clinical • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study. (PubMed, Diabetes Obes Metab) - "Multi-source pharmacovigilance can improve interpretation of GLP-1 postmarketing safety evidence in diabetes and obesity care. Findings should be interpreted as signal-prioritisation and medication-safety evidence, not as incidence, proof of causality, or population-level comparative risk, given the limited clinical interpretability of spontaneous-reporting data."

Adverse events • Journal • P4 data • Diabetes • Genetic Disorders • Hypoglycemia • Metabolic Disorders • Obesity • Pain

Association between GLP-1 receptor agonist use and incident malignancy in Japanese patients with type 2 diabetes: a Japanese claims database study (EASD 2026) - "Adults with T2D who initiated a GLP-1RA (dulaglutide, liraglutide, exenatide, or lixisenatide) were compared with patients without GLP-1RA exposure receiving other antidiabetic drugs. In this propensity score-matched analysis of Japanese adults with T2D, GLP-1RA use was associated with a significant increase in overall cancer incidence, with signals in several cancer sites. Exploratory analyses suggested possible heterogeneity across individual GLP-1RAs. Further studies are needed to clarify underlying mechanisms and differences across agents or patient subgroups."

Claims database • Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions. (PubMed, Clin Dermatol) - "Non-immunologic cutaneous adverse events comprise a substantial proportion of reported GLP-1RA-associated adverse events with differing rates among individual agents. Recognition of these reactions and appropriate supportive management may improve patient outcomes. Prospective studies are needed to better define their adverse event risk rates, mechanisms, and optimal management strategies."

Journal • Dermatology • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Pain • Pruritus • Type 2 Diabetes Mellitus

GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer's and Parkinson's disease. (PubMed, Front Neurosci) - "Recently, two phase 3 clinical trials testing the GLP-1 analogue Semaglutide (Wegovy, Ozempic) in patients with Alzheimer's disease did not show improvements...The GLP-1 analogue Liraglutide (Victoza), in contrast, has a much shorter half-life (13 h), and a phase 2 clinical trial showed improvements in cognitive tests after 1 year of treatment...Drugs that can cross the BBB well (exenatide, lixisenatide) show good protection, while a drug that cannot cross the BBB showed no effects (NLY01). Clearly, when treating CNS diseases, it is of importance to get the drug into the brain to ensure target engagement. This review will look at the clinical trials that have been conducted in more detail, describe the mode of action as derived from preclinical trials, and discuss novel strategies for getting GLP-1 receptor agonists into the brain to successfully treat CNS diseases."

Journal • Review • Alzheimer's Disease • CNS Disorders • Movement Disorders • Parkinson's Disease

Association of Glucagon-Like Peptide-1 Receptor Analogues and Laryngeal Symptoms in Obese Adults. (PubMed, Laryngoscope) - "GLP-1RA/GIP use in adults is linked to higher rates of laryngeal symptoms, most notably cough and voice and resonance disorders. While absolute risk differences were small, the large number of affected individuals underscores the potential clinical and public health relevance of these findings, in the context of the rapidly growing prevalence of GLP-1RA/GIP use."

Journal • Cough • Genetic Disorders • Head and Neck Cancer • Immunology • Obesity • Oncology • Respiratory Diseases • Solid Tumor

Influence of GLP-1 Receptor Agonists on Surgical and Nonsurgical Treatment of Ankle Osteoarthritis. (PubMed, Foot Ankle Spec) - "Patients were stratified by GLP-1 use, defined as ≥2 prescriptions separated by ≥6 months for semaglutide, liraglutide, dulaglutide, exenatide, or lixisenatide. HbA1c improved significantly in both diabetic groups, with slightly greater reduction in non-users (-6.0% vs -5.5%, P < .01)ConclusionObese GLP-1 users demonstrated lower rates of invasive ankle procedures, while diabetic GLP-1 users experienced higher arthroscopy utilization. These findings suggest that metabolic improvements may not uniformly translate to musculoskeletal benefit, warranting further investigation.Level of Evidence:III."

Journal • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Musculoskeletal Diseases • Obesity • Orthopedics • Osteoarthritis • Pain • Rheumatology • Type 2 Diabetes Mellitus

The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity. (PubMed, Pharmacol Res) - "Currently FDA-approved GLP-1 peptide receptor agonists used for the management of diabetes include liraglutide, semaglutide, and injectable dulaglutide...Orforglipron is a small molecule orally bioavailable medicine that is approved for the treatment of obesity. Retatrutide is an injectable peptide agonist of GLP-1R, GIPR, and the glucagon receptor that is undergoing clinical trials for the management of obesity and diabetes...A universal side effect of all GLP-1 receptor agonists includes nausea and vomiting. Consequently, the dosage is escalated sequentially over a period of weeks to mitigate these side effects."

Journal • Review • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder • Type 2 Diabetes Mellitus

Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis. (PubMed, Endocrine) - "Periconceptional or first-trimester exposure to GLP-1 RAs are not significantly associated with HDP risk. This available evidence is limited and indicating the need for large prospective studies to establish a possible association between GLP-1 RAs are not significantly associated with HDP risk."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Diabetes • Genetic Disorders • Gynecology • Hypertension • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

GLP-1 receptor agonists in Parkinson's disease: a meta-analysis revealing motor benefit and highlighting mood improvement. (PubMed, Front Neurol) - "We conducted a meta-analysis of 8 randomized trials (n = 850 PD patients) evaluating GLP-1RAs (Exenatide, Lixisenatide, Liraglutide, NLY01) versus placebo over treatment periods of 36-52 weeks and follow-up durations of 8-12 weeks (except one study with a 12-month follow-up). These findings support their therapeutic repurposing, with side effects being manageable. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251170531, CRD420251170531."

Journal • Retrospective data • Review • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Movement Disorders • Parkinson's Disease

GLP-1 Receptor Agonist Therapy in Children and Adolescents with Obesity: A Network Meta-Analysis of Differential Cardiometabolic Efficacy and Safety Profiles. (PubMed, Pharmacol Res) - "In this network meta-analysis of adolescents with overweight or obesity, GLP-1RAs showed differential cardiometabolic profiles. Semaglutide 2.4mg produced the largest point estimates for weight-related outcomes, dulaglutide 1.5mg and lixisenatide 20 ug for glycaemic endpoints, and exenatide 20 ug for systolic blood pressure. These findings are hypothesis-generating: most active-treatment comparisons were indirect, many nodes were informed by single trials, and SUCRA rankings should not be interpreted as evidence of definitive clinical superiority."

Journal • Retrospective data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Bayesian reappraisal of disease-modifying drug candidates for Parkinson's Disease (EAN 2026) - " We performed a Bayesian reappraisal of major DMT trials—covering cinpanemab, deferiprone, CoQ10, ambroxol, NLY01, liraglutide, lixisenatide, and exenatide—focusing on motor and non-motor outcomes, with standardized effect sizes, Bayes Factors (BF₁₀), and posterior probabilities. Bayesian analysis aligns with the strongest frequentist signals while clarifying ambiguous or inconsistent results, underscoring that the magnitude of the effect and evidential strength vary substantially across compounds. GLP-1R agonists show promising efficacy as DMT candidates for PD treatment. Pharmacokinetic and pharmacodynamic differences among the compounds could underlie the different efficacy profiles concerning the disease stage and different symptoms (i.e, motor or non-motor)."

CNS Disorders • Movement Disorders • Parkinson's Disease

Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. (PubMed, Ann Intern Med) - "Randomized controlled trials that compared pharmacologic treatments for weight management (dulaglutide, exenatide, liraglutide, lixisenatide, naltrexone-bupropion, orforglipron, phentermine, phentermine-topiramate, retatrutide, semaglutide, semaglutide-cagrilintide, tirzepatide, or any combination with or without lifestyle intervention [LI]) for overweight or obesity (body mass index ≥25 kg/m2) in adults for outcomes such as mortality, weight loss, and quality of life...American College of Physicians. (PROSPERO: CRD42023491646)."

Journal • Retrospective data • Review • Cardiovascular • Coronary Artery Disease • Diabetes • Genetic Disorders • Heart Failure • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus